Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 18, 2025
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2024
Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma.
Journal: The Journal of allergy and clinical immunology
Published: August 02, 2022
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 08, 2018
First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.
Journal: PloS one
Published: August 02, 2018
Showing 1-5 of 5
Last Updated: 09/26/2026